Xencor | XNCR - Operating Expenses


Xencor reported $82.38M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Cytokinetics USD 200.58M 4.46M Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
J&J USD 17.83B 388M Jun/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Xencor USD 82.38M 513K Mar/2026